semaglutide by novo nordisk Company of the year 2023: – Riding the wave Novo asks FDA to prevent
Description
A landmark study in 2023 found that semaglutide reduced major cardiovascular events by 20%, even in patients without diabetes
Another benefit is TrimRXs medication delivery service, which ensures you never run out of doses
These medications are approved to treat obesity and/or type 2 diabetes
Every individuals weight loss journey is unique, and at Sunrise Wellness, we believe in complementing this journey with state-of-the-art technology
Common Side Effects: Oily spotting, gas with discharge, urgent bowel movements, and fatty stools
Hence, semaglutide can provide dual benefit to patients with type 2 diabetes and obesity (diabesity)
